scholarly journals Follicular dendritic cell–dependent drug resistance of non-Hodgkin lymphoma involves cell adhesion–mediated Bim down-regulation through induction of microRNA-181a

Blood ◽  
2010 ◽  
Vol 116 (24) ◽  
pp. 5228-5236 ◽  
Author(s):  
Tint Lwin ◽  
Jianhong Lin ◽  
Yong Sung Choi ◽  
Xinwei Zhang ◽  
Lynn C. Moscinski ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Cell Adhesion ◽  
B Cell ◽  
Cell Survival ◽  
Hodgkin Lymphoma ◽  
Cell Lymphoma ◽  
Lymphoma Cells ◽  
Down Regulation ◽  
Non Hodgkin Lymphoma ◽  
Mantle Cell

AbstractFollicular dendritic cells (FDCs), an essential component of the lymph node microenvironment, regulate and support B-lymphocyte differentiation, survival, and lymphoma progression. Here, we demonstrate that adhesion of mantle cell lymphoma and other non-Hodgkin lymphoma cells to FDCs reduces cell apoptosis and is associated with decreased levels of the proapoptotic protein, Bim. Bim down-regulation is posttranscriptionally regulated via up-regulation of microRNA-181a (miR-181a). miR-181a overexpression decreases, whereas miR-181a inhibition increases Bim levels by directly targeting Bim. Furthermore, we found that cell adhesion–up-regulated miR-181a contributes to FDC-mediated cell survival through Bim down-regulation, implicating miR-181a as an upstream effector of the Bim-apoptosis signaling pathway. miR-181a inhibition and Bim upregulation significantly suppressed FDC-mediated protection against apoptosis in lymphoma cell lines and primary lymphoma cells. Thus, FDCs protect B-cell lymphoma cells against apoptosis, in part through activation of a miR-181a–dependent mechanism involving down-regulation of Bim expression. We demonstrate, for the first time, that cell-cell contact controls tumor cell survival and apoptosis via microRNA in mantle cell and other non-Hodgkin lymphomas. Regulation of microRNAs by B-cell–FDC interaction may support B-cell survival, representing a novel molecular mechanism for cell adhesion–mediated drug resistance and a potential therapeutic target in B-cell lymphomas.

Microenvironment-Mediated Bim Down-Regulation through Induction of Microrna-181a Protects Cells From Apoptosis In Mantle-Cell and Other Non-Hodgkin B-Cell Lymphomas

Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 3118-3118
Author(s):  
Tint Lwin ◽  
Jian-Hong Lin ◽  
Yong Sung Choi ◽  
Xinwei Zhang ◽  
Lynn Moscinski ◽  
...  
Keyword(s):  
Cell Adhesion ◽  
B Cell ◽  
Cell Survival ◽  
Conflicts Of Interest ◽  
B Cell Lymphoma ◽  
B Cell Lymphomas ◽  
Lymphoma Cells ◽  
Down Regulation ◽  
Essential Components ◽  
Mantle Cell

Abstract Abstract 3118 Follicular dendritic cells (FDCs), essential components of the lymph node microenvironment, regulate and support B lymphocyte differentiation, survival, and lymphoma progression. Here, we demonstrated that adhesion of mantle cell and other non-Hodgkin lymphoma cells to FDCs reduced cell apoptosis, associated with decreased levels of Bim, a pro-apoptotic protein. Bim down-regulation was epigenetically regulated via up-regulation of microRNA-181a (miR-181a). miR-181a overexpression decreased, whereas miR-181a inhibition increased Bim levels by directly targeting Bim. Furthermore, we found that cell adhesion-up-regulated miR-181a contributes to FDC-mediated cell survival through Bim down-regulation, implicating miR-181a as an upstream effector of the Bim-apoptosis signaling pathway. miR-181a inhibition and Bim up-regulation significantly suppressed FDC-mediated protection against apoptosis in lymphoma cell lines and primary lymphoma cells. Thus, FDCs protect B-cell lymphoma cells against apoptosis, in part through activation of a miR-181a-dependent mechanism involving down-regulation of Bim expression. We demonstrate, for the first time, that cell-cell contact controls tumor cell survival and apoptosis via microRNA in mantle cell and other non-Hodgkin lymphomas. Regulation of microRNAs by B-cell-FDC interaction may support B-cell survival, representing a novel molecular mechanism for cell-adhesion mediated drug resistance (CAM-DR) and a potential therapeutic target in B-cell lymphomas. Disclosures: No relevant conflicts of interest to declare.

Phase I and pharmacokinetic study of bendamustine hydrochloride in relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma

2010 ◽  
Vol 101 (9) ◽  
pp. 2054-2058 ◽  
Author(s):  
Michinori Ogura ◽  
Toshiki Uchida ◽  
Masafumi Taniwaki ◽  
Kiyoshi Ando ◽  
Takashi Watanabe ◽  
...  
Keyword(s):  
Phase I ◽  
B Cell ◽  
Mantle Cell Lymphoma ◽  
Hodgkin Lymphoma ◽  
Pharmacokinetic Study ◽  
Cell Lymphoma ◽  
Non Hodgkin Lymphoma ◽  
Mantle Cell

scholarly journals Phase 1–2 study of vorinostat (SAHA), cladribine and rituximab (SCR) in relapsed B‐cell non‐Hodgkin lymphoma and previously untreated mantle cell lymphoma

2019 ◽  
Vol 186 (6) ◽  
pp. 845-854 ◽  
Author(s):  
Stephen E. Spurgeon ◽  
Kamal Sharma ◽  
David F. Claxton ◽  
Christopher Ehmann ◽  
Jeffrey Pu ◽  
...  
Keyword(s):  
B Cell ◽  
Mantle Cell Lymphoma ◽  
Hodgkin Lymphoma ◽  
Cell Lymphoma ◽  
Phase 1 ◽  
Non Hodgkin Lymphoma ◽  
Mantle Cell

scholarly journals Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma

2010 ◽  
Vol 101 (9) ◽  
pp. 2059-2064 ◽  
Author(s):  
Ken Ohmachi ◽  
Kiyoshi Ando ◽  
Michinori Ogura ◽  
Toshiki Uchida ◽  
Kuniaki Itoh ◽  
...  
Keyword(s):  
B Cell ◽  
Mantle Cell Lymphoma ◽  
Hodgkin Lymphoma ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Cell Lymphoma ◽  
Non Hodgkin Lymphoma ◽  
Multicenter Phase ◽  
Mantle Cell

Randomized phase II study of a bendamustine monotherapy schedule for relapsed or refractory low-grade B-cell non-Hodgkin lymphoma or mantle cell lymphoma (RABBIT-14)

2017 ◽  
Vol 59 (7) ◽  
pp. 1606-1613
Author(s):  
Kuniaki Itoh ◽  
Tadahiko Igarashi ◽  
Hiroyuki Irisawa ◽  
Nobuyuki Aotsuka ◽  
Shinichi Masuda ◽  
...  
Keyword(s):  
B Cell ◽  
Mantle Cell Lymphoma ◽  
Hodgkin Lymphoma ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Cell Lymphoma ◽  
Low Grade ◽  
Non Hodgkin Lymphoma ◽  
Randomized Phase Ii ◽  
Mantle Cell

Primary mantle cell lymphoma complicated with cutaneous diffuse large B-cell lymphoma, leg type: a rare case report of composite non-Hodgkin lymphoma in different organs

2020 ◽  
Author(s):  
Yanfeng Jiang ◽  
Zhiming Zeng ◽  
Lihua Yang ◽  
Jie Zeng ◽  
Fengyan Qin ◽  
...  
Keyword(s):  
B Cell ◽  
Mantle Cell Lymphoma ◽  
Hodgkin Lymphoma ◽  
Rare Case ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Non Hodgkin Lymphoma ◽  
Large B Cell Lymphoma ◽  
Mantle Cell ◽  
Large B Cell

Abstract Background Composite lymphomas (CLs) are a kind of rare disease that two distinct categories of lymphomas occur in the same patient. Histologically, composite lymphomas can be composed of a Hodgkin’s lymphoma and a non-Hodgkin lymphoma or two distinct non-Hodgkin lymphomas. So far, most of the cases have been reported to occur in a single anatomical site or mass. Case presentation: A 61-year-old man without any B-type symptoms complained of an enlarging mass in the abdomen for one month. A 10 × 10 cm abdominal mass could be touched in the hypogastric region. Through pathological biopsy, mantle cell lymphoma can be diagnosed. After one cycle chemotherapy regimen of FCD, red rashes and blisters came out on the patient's right lower extremity. Cutaneous diffuse large B-cell lymphoma (DLBCL) was diagnosed by skin biopsy. In this report, we describe a case of composite lymphoma occurring in different organs, which consisted of primary mantle cell lymphoma (MCL) and cutaneous DLBCL, leg type. The patient then received a series of chemotherapy regimens without rituximab then achieved partial response (PR). Conclusions To our knowledge, this is a rare case of CLs occurring in different anatomic sites that were treated by chemotherapy and achieved PR. As we learn more about the mechanisms and treatment of CLs, we look forward to more treatment options in the future for patients to give them a better prognosis.

scholarly journals A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B‐cell non‐Hodgkin lymphoma and mantle cell lymphoma

2014 ◽  
Vol 165 (6) ◽  
pp. 768-776 ◽  
Author(s):  
Michinori Ogura ◽  
Kiyoshi Ando ◽  
Tatsuya Suzuki ◽  
Kenichi Ishizawa ◽  
Sung Yong Oh ◽  
...  
Keyword(s):  
B Cell ◽  
Mantle Cell Lymphoma ◽  
Hodgkin Lymphoma ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Cell Lymphoma ◽  
Multicentre Phase ◽  
Non Hodgkin Lymphoma ◽  
Mantle Cell
Sign in / Sign up

Export Citation Format

Share Document